SMARCA2 and cancer: For example, a GSH-inducible SMARCA2/4-targeting PROTAC demonstrates selective degradation of SMARCA2/4 in cancer cells, promoting DNA damage and apoptosis while inhibiting tumor growth in xenograft models without adverse effects on normal cells (Ji et al., 2024).